Collaboration: Iktos and Italfarmaco

Italfarmaco SpA and Iktos announced a collaboration on June 18, 2024, to "develop next-generation HDAC inhibitors for non-oncological diseases, leveraging Iktos's AI-driven Makya and Spaya platforms for innovative molecule design and synthesis." The initiative focuses on drug-discovery acceleration, with particular emphasis on conditions affecting the central nervous system, using Makya (generative AI for chemistry) and Spaya (AI-driven retrosynthesis) to streamline discovery. No financial figures, timelines, or quantified outcomes are disclosed; the announcement references a fuller press release on GlobeNewswire.

Iktos is a generative-AI drug-design company whose de novo molecule-design platform is used directly by partner pharma companies' medicinal chemists.

This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.